PON1 and chronic myelogenous leukemia, BCR-ABL1 positive: The paraoxonase (PON) assay showed that treatment of CML caused a remarkable loss of PON activity of HDL3, around 72% lower PON activity (p < 0.01) than with HDL3 alone (Figure 2C).